SCHEMBL588713

SCHEMBL588713

COC(=O)C1=C(O)CCc2cc(OC)ccc21

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.58
MAPT P10636 7/20 0.58
KDM4E B2RXH2 5/20 0.58
GLA P06280 2/20 0.58
ATM Q13315 2/20 0.58
GAA P10253 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
NPC1 O15118 6/20 0.48
SMN1; SMN2 Q16637 5/20 0.48
MIF P14174 4/20 0.47
CYP26A1 O43174 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
NFKB1 P19838 3/20 0.45
NFKB2 Q00653 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4030552 0.87 KDM4E (0.57) RAB9AMAPTKDM4EGLAATM
SCHEMBL588072 0.82 MAPK14 (0.43) RAB9AMAPTKDM4EGLAATM
SCHEMBL587938 0.82 SRD5A1 (0.48) RAB9AMAPTKDM4EGLAATM
SCHEMBL14812784 0.77 MAPT (0.55) RAB9AMAPTKDM4EGLAATM
SCHEMBL9376500 0.77 MAPT (0.52) RAB9AMAPTKDM4EGAANPC1
SCHEMBL17108416 0.75 MPO (0.59) RAB9AMAPTKDM4EGLAATM
SCHEMBL6648373 0.73 L3MBTL1 (0.42) MAPTKDM4ETDP1L3MBTL1SMN1; SMN2
SCHEMBL14355553 0.73 MPO (0.56) RAB9AMAPTKDM4EGLAATM
SCHEMBL30940179 0.73 MPO (0.56) RAB9AMAPTKDM4EGLAATM
SCHEMBL20644283 0.73 MAPK14 (0.59) RAB9AMAPTKDM4EGLAATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8258168-B2 2H or 3H-benzo[E]indazol-1-YL carbamate derivatives, the preparation and therapeutic use thereof SANOFI (FR) 2012-09-04 US disclosed
US-20120108584-A1 2H OR 3H-BENZO[E]INDAZOL-1-YL CARBAMATE DERIVATIVES, THE PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2012-05-03 US disclosed
US-8114899-B2 2H- or 3H-benzo[e]indazol-1-yl carbamate derivatives, the preparation and therapeutic use thereof SANOFI-AVENTIS (FR) 2012-02-14 US disclosed
US-20090143380-A1 2H- OR 3H-BENZO[E]INDAZOL-1-YL CARBAMATE DERIVATIVES, THE PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-06-04 US disclosed
US-7501449-B2 2H -or 3H-benzo[e]indazol-1-yl carbamate derivatives, the preparation and therapeutic use thereof SANOFI-AVENTIS (FR) 2009-03-10 US disclosed
US-20070105932-A1 2H-or 3H-benzo[e]indazol-1-yl carbamate derivatives, the preparation and therapeutic use thereof SANOFI-AVENTIS (FR) 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105932-A1 2H-or 3H-benzo[e]indazol-1-yl carbamate derivatives, the preparation and therapeutic use thereof GLS2, GLS, CYP11B2 RAB9A 1148/4885MAPT 2383/4885KDM4E 445/4885
US-20090143380-A1 2H- OR 3H-BENZO[E]INDAZOL-1-YL CARBAMATE DERIVATIVES, THE PREPARATION AND THERAPEUTIC USE THEREOF GLS2, GLS, SDHA RAB9A 1178/4885MAPT 2287/4885KDM4E 432/4885
US-20120108584-A1 2H OR 3H-BENZO[E]INDAZOL-1-YL CARBAMATE DERIVATIVES, THE PREPARATION AND THERAPEUTIC USE THEREOF GLS2, GLS, SDHA RAB9A 988/4885MAPT 2237/4885KDM4E 456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.